A Multicentre, Multinational, Randomised, Double-Blind, Parallel-Group Study Comparing ACR16 45 mg Once-Daily or Twice-Daily Versus Placebo for the Symptomatic Treatment of Huntington's Disease
Latest Information Update: 01 Sep 2023
At a glance
- Drugs Pridopidine (Primary)
- Indications Huntington's disease
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms MermaiHD
- Sponsors Teva Branded Pharmaceutical Products R&D
- 22 Feb 2023 Results of pooled analysis assessing the pridopidine's effect on the QT interval and investigated its cardiac safety profile from NCT02006472, NCT00724048 and NCT00665223 trials, published in the Neurology and Therapy.
- 18 Jun 2015 Pooled safety analysis ( combination with antidepressants or antipsychotics), results presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.
- 01 Dec 2011 Results published in The Lancet Neurology.